Hospital Universitari de Bellvitge -ko ikertzaileekin lankidetzan egindako argitalpenak (374)

2024

  1. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

    The Lancet, Vol. 403, Núm. 10437, pp. 1649-1659

  2. Clinical suspicion, diagnosis and management of cardiac amyloidosis: update and executive summary

    Revista Clinica Espanola, Vol. 224, Núm. 5, pp. 288-299

  3. Combinational Diuretics in Heart Failure

    Current Heart Failure Reports

  4. Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab

    Breast Cancer Research and Treatment

  5. Design and baseline characteristics of SALT-HF trial: hypertonic saline therapy in ambulatory heart failure

    ESC Heart Failure

  6. Invasive Treatment Strategy in Adults With Frailty and Non-ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of a Randomized Clinical Trial

    JAMA network open, Vol. 7, Núm. 3, pp. e240809

  7. Non-atherosclerotic acute cardiac syndromes: spontaneous coronary artery dissection and Takotsubo syndrome. Comparison of long-term clinical outcomes

    Coronary artery disease, Vol. 35, Núm. 1, pp. 50-58

  8. Prognosis after heart transplant in patients with hypertrophic and restrictive cardiomyopathy. A nationwide registry analysis

    Revista Espanola de Cardiologia, Vol. 77, Núm. 4, pp. 304-313

  9. Prognosis of acute heart failure in patients followed up in nursing homes in Spain: Results from the RICA registry

    Medicina Clinica, Vol. 162, Núm. 4, pp. 157-162

  10. Repetitive ambulatory levosimendan as a bridge to heart transplantation

    Revista Espanola de Cardiologia, Vol. 77, Núm. 4, pp. 290-301

  11. Review of the allocation criteria for heart transplant in Spain in 2023. SEC-Heart Failure Association/ONT/SECCE consensus document

    Revista Espanola de Cardiologia, Vol. 77, Núm. 1, pp. 69-78

  12. Risk prediction of major cardiac adverse events and all-cause death following covid-19 hospitalization at one year follow-up: The HOPE-2 score

    European Journal of Internal Medicine

  13. Sex differences in clinical characteristics and outcomes in the CLOROTIC (combining loop with thiazide diuretics for decompensated heart failure) trial

    Revista Clinica Espanola, Vol. 224, Núm. 2, pp. 67-76

  14. The significance of metabolic alkalosis on acute decompensated heart failure: the ALCALOTIC study

    Clinical Research in Cardiology

  15. Use of a surgically implanted, nondischargeable, extracorporeal continuous flow circulatory support system as a bridge to heart transplant

    Revista espanola de cardiologia (English ed.), Vol. 77, Núm. 1, pp. 39-49

2023

  1. A blood microRNA classifier for the prediction of ICU mortality in COVID-19 patients: a multicenter validation study

    Respiratory Research, Vol. 24, Núm. 1

  2. A single-arm study design with non-inferiority and superiority time-to-event endpoints: a tool for proof-of-concept and de-intensification strategies in breast cancer

    Frontiers in Oncology, Vol. 13

  3. Antithrombotic Strategy in Secondary Prevention for High-Risk Patients with Previous Acute Coronary Syndrome: Overlap between the PEGASUS Eligibility and the COMPASS Eligibility in a Large Multicenter Registry

    American Journal of Cardiovascular Drugs, Vol. 23, Núm. 1, pp. 77-87

  4. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer

    Annals of Oncology, Vol. 34, Núm. 9, pp. 783-795

  5. Benefits of dapagliflozin in the whole spectrum of heart failure in clinical practice: the RICA registry

    Future cardiology, Vol. 19, Núm. 6, pp. 323-332